In this regard, Chen et al. demonstrated a potential therapeutic role for hepcidin in alleviating steatohepatitis and fibrosis in NASH-induced animal models via recombinant adeno-associated virus genome 2 serotype 8 vector expressing Hamp (rAAV2/8-Hamp)-mediated hepcidin intervention. The gene discussed is HAMP; the disease is metabolic dysfunction-associated steatohepatitis.